Canada Post Corp Registered Pension Plan Acquires 22,986 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Canada Post Corp Registered Pension Plan increased its Bristol Myers Squibb stake by 35.9% in the fourth quarter, buying 22,986 additional shares. The pension plan now owns 87,063 shares valued at about $4.7 million.
• Bristol Myers Squibb also saw insider selling, with EVP David V. Elkins selling 30,000 shares for about $1.85 million. After the sale, he still held 159,248 shares.
• The company reported better-than-expected quarterly results, with EPS of $1.58 versus the $1.42 estimate and revenue of $11.49 billion versus $10.93 billion expected. BMY also pays a quarterly dividend of $0.63 per share, yielding about 4.4% annually.

Canada Post Corp Registered Pension Plan lifted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 35.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 87,063 shares of the biopharmaceutical company's stock after acquiring an additional 22,986 shares during the quarter. Canada Post Corp Registered Pension Plan's holdings in Bristol Myers Squibb were worth $4,696,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of BMY. Physician Wealth Advisors Inc. raised its holdings in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 202 shares in the last quarter. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb in the second quarter worth $25,000. EQ Wealth Advisors LLC bought a new position in Bristol Myers Squibb in the fourth quarter worth $32,000. Garner Asset Management Corp bought a new position in Bristol Myers Squibb in the fourth quarter worth $35,000. Finally, Beacon Financial Strategies CORP bought a new position in Bristol Myers Squibb in the fourth quarter worth $38,000. 76.41% of the stock is owned by institutional investors.

Insider Activity

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the business's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.05% of the stock is currently owned by corporate insiders.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb’s $15.2 billion collaboration and licensing deal with Hengrui Pharma expands its pipeline with 13 early-stage programs, a major long-term growth catalyst. Bristol-Myers Strikes $15.2 Billion China Drug Deal
• Positive Sentiment: Zacks Research raised earnings estimates for FY2026, FY2027, FY2028 and several quarterly periods, suggesting improved profitability expectations for BMY. MarketBeat Bristol Myers Squibb estimates update
• Positive Sentiment: Tempus expanded its strategic collaboration with Bristol Myers Squibb to use AI and real-world data to improve clinical development success in oncology and neuroscience. Tempus expands strategic collaboration with Bristol Myers Squibb
• Positive Sentiment: Tigerlily Foundation announced a collaboration with Bristol Myers Squibb to expand clinical trial access and reduce participation barriers, supporting the company’s ESG and patient-access profile. Tigerlily Foundation collaborates with Bristol Myers Squibb
• Neutral Sentiment: Bristol Myers Squibb presented at the Bank of America Global Healthcare Conference, which is typically informational rather than a direct stock-moving event. Bristol-Myers Squibb Company presents at conference transcript
• Neutral Sentiment: Analyst commentary on BMY’s valuation and “buy, sell, or hold” status adds context, but it does not appear to be a new fundamental catalyst. Bristol-Myers Squibb buy sell or hold post Q1 earnings
• Negative Sentiment: One article highlighted a recent pullback in BMY shares, reminding investors that momentum has been uneven despite the recent rally. Bristol-Myers Squibb Stock Falls 3.9% After May 2026 Pullback

Bristol Myers Squibb Trading Up 0.5%

NYSE:BMY opened at $57.04 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The company has a market cap of $116.48 billion, a PE ratio of 16.02, a price-to-earnings-growth ratio of 0.16 and a beta of 0.26. The company has a 50 day simple moving average of $58.63 and a two-hundred day simple moving average of $55.35.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.42 by $0.16. The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business's quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.31 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date was Thursday, April 2nd. Bristol Myers Squibb's payout ratio is currently 70.79%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BMY. Barclays began coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They set an "overweight" rating and a $75.00 target price for the company. Cantor Fitzgerald raised their target price on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a "neutral" rating in a research note on Wednesday, April 8th. Wall Street Zen raised shares of Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research note on Sunday, April 19th. Guggenheim reaffirmed a "buy" rating and set a $72.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Finally, Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They set a "sector perform" rating and a $60.00 target price for the company. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of "Hold" and a consensus price target of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.